Literature DB >> 33669022

Vascular Inflammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation.

Paul Marczynski1, Myriam Meineck1, Ning Xia2, Huige Li2, Daniel Kraus1, Wilfried Roth3, Tamara Möckel1, Simone Boedecker1, Andreas Schwarting1, Julia Weinmann-Menke1.   

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease and patients are under an increased risk for cardiovascular (CV) events and mortality. The increased CV risk for patients with SLE seems to be caused by a premature and accelerated atherosclerosis, attributable to lupus-specific risk factors (i.e., increased systemic inflammation, altered immune status), apart from traditional CV risk factors. To date, there is no established experimental model to explore the pathogenesis of this increased CV risk in SLE patients.
METHODS: Here we investigated whether MRL-Faslpr mice, which develop an SLE-like phenotype, may serve as a model to study lupus-mediated vascular disease. Therefore, MRL-Faslpr, MRL-++, and previously generated Il6-/- MRL-Faslpr mice were used to evaluate vascular changes and possible mechanisms of vascular dysfunction and damage.
RESULTS: Contrary to MRL-++ control mice, lupus-prone MRL-Faslpr mice exhibited a pronounced vascular and perivascular leukocytic infiltration in various organs; expression of pro-inflammatory cytokines in the aorta and kidney was augmented; and intima-media thickness of the aorta was increased. IL-6 deficiency reversed these changes and restored aortic relaxation.
CONCLUSION: Our findings demonstrate that the MRL-Faslpr mouse model is an excellent tool to investigate vascular damage in SLE mice. Moreover, IL-6 promotes vascular inflammation and damage and could potentially be a therapeutic target for the treatment of accelerated arteriosclerosis in SLE.

Entities:  

Keywords:  Intima media thickness; T Cells; antibody; cardiovascular disease; cytokines; macrophage; systemic lupus erythematosus

Mesh:

Substances:

Year:  2021        PMID: 33669022      PMCID: PMC7956579          DOI: 10.3390/ijms22052291

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  39 in total

1.  IL-34-Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-Faslpr Mice.

Authors:  Yukihiro Wada; Hilda M Gonzalez-Sanchez; Julia Weinmann-Menke; Yasunori Iwata; Amrendra K Ajay; Myriam Meineck; Vicki R Kelley
Journal:  J Am Soc Nephrol       Date:  2019-01-08       Impact factor: 10.121

2.  Systemic Lupus Erythematosus and Endothelial Dysfunction: A Close Relationship.

Authors:  Edoardo Sciatti; Ilaria Cavazzana; Enrico Vizzardi; Ivano Bonadei; Micaela Fredi; Mara Taraborelli; Romina Ferizi; Marco Metra; Angela Tincani; Franco Franceschini
Journal:  Curr Rheumatol Rev       Date:  2019

Review 3.  Cardiovascular disease in systemic lupus erythematosus: A comprehensive update.

Authors:  Mayra Giannelou; Clio P Mavragani
Journal:  J Autoimmun       Date:  2017-06-09       Impact factor: 7.094

4.  Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.

Authors:  Hannes Cash; Manfred Relle; Julia Menke; Christoph Brochhausen; Simon A Jones; Nicholas Topley; Peter R Galle; Andreas Schwarting
Journal:  J Rheumatol       Date:  2009-12-01       Impact factor: 4.666

5.  Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies.

Authors:  Marko Yurkovich; Kateryna Vostretsova; Wenjia Chen; J Antonio Aviña-Zubieta
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-04       Impact factor: 4.794

6.  Lupus-prone New Zealand Black/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells.

Authors:  S G Thacker; D Duquaine; J Park; M J Kaplan
Journal:  Lupus       Date:  2010-01-12       Impact factor: 2.911

Review 7.  The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies.

Authors:  Frances Rees; Michael Doherty; Matthew J Grainge; Peter Lanyon; Weiya Zhang
Journal:  Rheumatology (Oxford)       Date:  2017-11-01       Impact factor: 7.580

Review 8.  Arterial ageing: from endothelial dysfunction to vascular calcification.

Authors:  M Tesauro; A Mauriello; V Rovella; M Annicchiarico-Petruzzelli; C Cardillo; G Melino; N Di Daniele
Journal:  J Intern Med       Date:  2017-03-27       Impact factor: 8.989

9.  Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: a meta-analysis.

Authors:  Jianwen Ding; Shujun Su; Tao You; Tingting Xia; Xiaoying Lin; Zhaocong Chen; Liqun Zhang
Journal:  Clinics (Sao Paulo)       Date:  2020-10-19       Impact factor: 2.365

10.  Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.

Authors:  Daniel J Wallace; Vibeke Strand; Joan T Merrill; Serghei Popa; Alberto J Spindler; Alicia Eimon; Michelle Petri; Josef S Smolen; Joseph Wajdula; Jared Christensen; Cheryl Li; Annette Diehl; Michael S Vincent; Jean Beebe; Paul Healey; Sudhakar Sridharan
Journal:  Ann Rheum Dis       Date:  2016-09-26       Impact factor: 19.103

View more
  1 in total

1.  Vascular Inflammation in Mouse Models of Systemic Lupus Erythematosus.

Authors:  Holly Ryan; Laurence Morel; Erika Moore
Journal:  Front Cardiovasc Med       Date:  2022-03-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.